Femara is indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In early breast cancer, it is indicated for initial or extended adjuvant therapy. In advanced cases, it is indicated as first line treatment, or after tamoxifen therapy has failed. Femara is not indicated for hormone receptor-negative breast cancer.
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.
